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Background
As single agents, durvalumab (MEDI4736), a human
IgG1 anti-PD-L1 antibody, and tremelimumab, a human
IgG2 anti-CTLA-4 antibody, have shown acceptable
safety profiles and antitumor activity. Similar to other
anti-PD-L1/anti-PD-1 monotherapies, durvalumab has
shown greater objective tumor response rates in PD-L1-
positive patients compared with PD-L1-negative
patients. Anti-CTLA4 therapies activate T-cells and may
increase immune infiltrate and PD-L1 expression in
tumor cells and tumor infiltrating immune cells. Thus,
combination therapy with durvalumab and tremelimu-
mab could be active in NSCLC regardless of baseline
PD-L1 expression.
Methods
This is a phase 1, open-label, dose-escalation/expansion
study (NCT02000947) of D+T in patients with Stage III/
IV NSCLC (any number of prior lines of therapy; immu-
notherapy-naïve). The primary endpoint is safety and
tolerability; secondary endpoints include investigator-
reported RECIST v1.1 response. PD-L1 expression was
tested retrospectively using an immunohistochemical
assay (Ventana).
Results
As of 1 June 2015, 102 patients received treatment in the
dose escalation phase; combinations of durvalumab [3 mg/
kg (D3) to 20 mg/kg (D20) every 2 (q2w) or 4 weeks
(q4w)] and tremelimumab [1 mg/kg (T1) to 3 mg/kg (T3)]
q4w, plus a D15 + T10 combination, were explored.
Across all cohorts, 80% and 42% of patients had ≥1 treat-
ment-related AE (any Grade and Grade 3/4, respectively);
28% discontinued treatment due to a related AE. A greater
frequency of AEs, without a corresponding increase in
tumor response, was seen with increasing T dose. In the
combined T1 cohort (D10–D20), 73% and 30% of patients
had ≥1 related AE (any Grade and Grade 3/4, respec-
tively); 16% discontinued treatment due to a related AE.
There were 3 treatment-related deaths (myasthenia gravis,
T1; pericardial effusion, T1; neuromuscular disorder, T3).
84 patients (73 EGFR/ALK wild-type; 77 non-squa-
mous; 48 with ≥2 prior lines of therapy) were evaluable
for response (Table 1). The overall response rate (con-
firmed+unconfirmed) was 25%. Higher response rates
were observed in those with 1 vs ≥2 prior therapies.
Response rates do not appear dependent on PD-L1 sta-
tus: 35% (PD-L1-positive), 22% (PD-L1-negative, <25%
tumor cell staining) and 33% (PD-L1-negative, 0%
tumor cell staining). Similar findings were observed for
the combined T1 cohort. D+T also showed good dur-
ability of response similar to that seen for monotherapy.
Conclusions
D+T at selected phase 3 dose (D20, T1) has a manage-
able tolerability profile and anti-tumor activity in
NSCLC. Unlike anti- PD-1/PD-L1 monotherapies, the
combination of D+T appears to be active regardless of
PD-L1 status, including even in patients with no tumor
cell membrane PD-L1 staining, a setting where patients
would not be expected to derive significant benefit from
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anti-PD-1/PD-L1 monotherapy over current standard of
care [1,2].
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Table 1 Response rates (Confirmed/unconfirmed with ≥16 weeks follow-up)
Overall population EGFR/ALK wild-type population
All cohorts Combined cohort: D10–20 q4w or q2w + T1 All cohorts Combined cohort: D10–20 q4w or q2w + T1
n/N (%) 95% CI n/N (%) 95% CI n/N (%) 95% CI n/N (%) 95% CI
All patients 21/84 (25) 16–36 11/39 (28) 15–45 21/73 (29) 19–41 11/34 (32) 17–51
PD-L1+ (≥25%) 7/20 (35) 15–59 3/9 (33) 8–70 7/17 (41) 18–67 3/9 (33) 8–70
PD-L1- (<25%) 11/49 (22) 12–37 6/23 (26) 10–48 11/45 (24) 13–40 6/19 (32) 13–57
PD-L1- (0%) 9/27 (33) 17–54 6/12 (50) 21–79 9/26 (35) 17–56 6/11 (55) 23–83
All 2L patients 15/32 (47) 29–65 7/16 (44) 20–70 15/31 (48) 30–67 7/15 (47) 21–73
PD-L1+ (≥25%) 6/8 (75) 35–97 2/3 (67) 9–99 6/8 (75) 35–97 2/3 (67) 9–99
PD-L1- (<25%) 7/18 (39) 17–64 4/11 (36) 11–69 7/17 (41) 18–67 4/10 (40) 12–74
PD-L1- (0%) 6/8 (75) 35–97 4/5 (80) 28–100 6/8 (75) 35–97 4/5 (80) 28–100
2L, second line: 1 prior line of therapy, receiving D+T in second line
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